Lisa Seitz

1.1k total citations
35 papers, 780 citations indexed

About

Lisa Seitz is a scholar working on Oncology, Immunology and Physiology. According to data from OpenAlex, Lisa Seitz has authored 35 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Immunology and 7 papers in Physiology. Recurrent topics in Lisa Seitz's work include Adenosine and Purinergic Signaling (7 papers), Chemokine receptors and signaling (6 papers) and Immune Cell Function and Interaction (6 papers). Lisa Seitz is often cited by papers focused on Adenosine and Purinergic Signaling (7 papers), Chemokine receptors and signaling (6 papers) and Immune Cell Function and Interaction (6 papers). Lisa Seitz collaborates with scholars based in United States, Germany and Denmark. Lisa Seitz's co-authors include Jay P. Powers, Juan C. Jaén, Daniel J. Dairaghi, Thomas J. Schall, Trageen Baumgart, Linda Ertl, Yu Wang, J. Charles Jennette, Bao Lu and Mark E.T. Penfold and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lisa Seitz

34 papers receiving 759 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Seitz United States	12	356	253	158	157	135	35	780
Linda Ertl United States	12	494 1.4×	256 1.0×	168 1.1×	138 0.9×	189 1.4×	27	904
Trageen Baumgart United States	7	359 1.0×	241 1.0×	158 1.0×	108 0.7×	85 0.6×	9	641
Antonia Potarca United States	8	412 1.2×	383 1.5×	331 2.1×	124 0.8×	106 0.8×	16	919
Margherita Gigante Italy	21	362 1.0×	283 1.1×	195 1.2×	440 2.8×	244 1.8×	38	1.2k
Hiroko Kanda Japan	18	300 0.8×	110 0.4×	105 0.7×	130 0.8×	95 0.7×	55	823
Anna J. Strachan Australia	7	326 0.9×	52 0.2×	59 0.4×	136 0.9×	54 0.4×	8	589
Tsukasa Takemura Japan	20	203 0.6×	139 0.5×	571 3.6×	322 2.1×	71 0.5×	55	1.1k
Shizuyo Tsujimura Japan	16	286 0.8×	92 0.4×	64 0.4×	101 0.6×	234 1.7×	33	969
Samy Hakroush Germany	15	222 0.6×	285 1.1×	391 2.5×	264 1.7×	163 1.2×	54	954
Marjolein Garsen Netherlands	10	201 0.6×	86 0.3×	210 1.3×	313 2.0×	44 0.3×	11	829

Countries citing papers authored by Lisa Seitz

Since Specialization

Citations

This map shows the geographic impact of Lisa Seitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Seitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Seitz more than expected).

Fields of papers citing papers by Lisa Seitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Seitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Seitz. The network helps show where Lisa Seitz may publish in the future.

Co-authorship network of co-authors of Lisa Seitz

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Seitz. A scholar is included among the top collaborators of Lisa Seitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Seitz. Lisa Seitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghasemi, Mohammad, Ji Yun Kim, Lisa Seitz, et al.. (2025). Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants. British Journal of Clinical Pharmacology. 91(12). 3366–3377.

Seitz, Lisa, et al.. (2024). MSR162 Identification of Patients With Obesity, Based on Their Comorbidities. Value in Health. 27(12). S470–S470. 1 indexed citations

Groot, Amber E. de, Soonweng Cho, Rebecca D. Ray, et al.. (2024). Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells. Cancer Research. 84(12). 1978–1995. 8 indexed citations

Groot, Amber E. de, Amy E. Anderson, Rebecca D. Ray, et al.. (2023). 475 Fc-silent anti-TIGIT antibodies potentiate anti-tumor immunity without depleting regulatory T cells. SHILAP Revista de lepidopterología. A534–A534. 1 indexed citations

Seitz, Lisa, Manmohan R. Leleti, Jay P. Powers, et al.. (2018). Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response. Annals of Oncology. 29. viii665–viii665. 2 indexed citations

Seitz, Lisa, Lixia Jin, Manmohan R. Leleti, et al.. (2018). Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Investigational New Drugs. 37(4). 711–721. 48 indexed citations

Talay, Oezcan, Lisa A. Marshall, Maureen K. Reilly, et al.. (2017). Abstract 4600: Potent and selective C-C chemokine receptor (CCR4) antagonists potentiate anti-tumor immune responses by inhibiting regulatory T cells (Treg). Cancer Research. 77(13_Supplement). 4600–4600. 3 indexed citations

Bekker, Pirow, Daniel J. Dairaghi, Lisa Seitz, et al.. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE. 11(10). e0164646–e0164646. 115 indexed citations

Pollock, Richard F., Anne‐Marie Kappelgaard, & Lisa Seitz. (2015). An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery. 12(3). 353–360. 8 indexed citations

10.

Wilke, Thomas, S. Mueller, A. Groth, et al.. (2015). Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 14(1). 14–14. 21 indexed citations

11.

Johnson, Michael G., Jim Liu, An‐Rong Li, et al.. (2014). Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD2 receptors CRTH2 and DP. Bioorganic & Medicinal Chemistry Letters. 24(13). 2877–2880. 1 indexed citations

12.

Wilke, Thomas, A. Groth, Andreas Fuchs, et al.. (2014). Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients. Diabetes Research and Clinical Practice. 106(2). 275–285. 17 indexed citations

13.

Seitz, Lisa, et al.. (2014). Health Economics Analysis of Insulin Aspart vs. Regular Human Insulin in Type 2 Diabetes Patients, Based on Observational Real life Evidence from General Practices in Germany. Experimental and Clinical Endocrinology & Diabetes. 122(9). 517–522. 5 indexed citations

14.

Wilke, Thomas, A. Groth, Andreas Fuchs, et al.. (2014). Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 449,368 german patients. Value in Health. 17(3). A260–A260. 1 indexed citations

15.

Sullivan, Timothy J., Zhenhua Miao, Daniel J. Dairaghi, et al.. (2013). CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. American Journal of Physiology-Renal Physiology. 305(9). F1288–F1297. 76 indexed citations

16.

Miao, Zhenhua, Yu Wang, Jay P. Powers, et al.. (2013). The CCR4 antagonist CCX6239 for the treatment of allergic airways disease. European Respiratory Journal. 42(Suppl 57). 3535–3535. 1 indexed citations

17.

Meinhardt, Udo, Urs Eiholzer, Lisa Seitz, Mette Bøgelund, & Anne‐Marie Kappelgaard. (2013). Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay. Expert Review of Medical Devices. 11(1). 31–38. 11 indexed citations

18.

Sullivan, Timothy J., Zhenhua Miao, Bin Zhao, et al.. (2013). Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism. 62(11). 1623–1632. 43 indexed citations

19.

Xiao, Hong, Daniel J. Dairaghi, Jay P. Powers, et al.. (2013). C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN. Journal of the American Society of Nephrology. 25(2). 225–231. 257 indexed citations

20.

Liu, Jiwen, Yingcai Wang, Michael G. Johnson, et al.. (2011). Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists. Bioorganic & Medicinal Chemistry Letters. 22(4). 1686–1689. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact